GlaxoSmithKline's CEO Andrew Witty outlines new global public health agenda

23 February 2009

Andrew Witty, chief executive of UK-headquartered drug major GlaxoSmithKline, has set out - in a speech titled Big Pharma a Catalyst  for Change - an ambitious new agenda to tackle the challenges of  improving global public health. Speaking at the Harvard Medical School  in Massachusetts, USA, Mr Witty described the task facing the world's  second-largest pharmaceutical firm by prescription sales as "huge." He  said: "Africa, for example, has 34 of the 50 poorest countries in the  world and suffers 24% of the global disease burden."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight